Galera Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities:
Net loss
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Acquired in-process research and development
Depreciation and amortization
Noncash interest expense
Share-based compensation expense
Deferred tax liability
Write-off of acquired intangible asset
Write-off of goodwill
Deferred tax benefit
Change in fair value of warrants
Gain on sale of dismutase mimetics assets
Gain on extinguishment of debt
Loss on disposal of property and equipment
Changes in operating assets and liabilities:
Refundable PDUFA fee
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Other liabilities

Cash used in operating activities
Investing activities:
Purchases of short-term investments
Proceeds from sales of short-term investments
Cash paid for acquisition of Nova
Purchase of property and equipment
Proceeds from sale of property and equipment
Proceeds from sale of dismutase mimetics asset
Cash provided by investing activities
Financing activities:
Proceeds from royalty purchase agreement
Proceeds from the sale of common stock and common stock warrants in private placement, net of issuance costs
Proceeds from the sale of common stock and common stock warrants in registered direct offering, net of issuance costs
Proceeds from the sale of common stock under the Open Market Sale Agreement, net of issuance costs
Proceeds from the exercise of common stock warrants
Proceeds from exercise of stock options
Cash provided by financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental schedule of non-cash investing and financing activities:
Issuance of warrants in conjunction with amendment to the Royalty Purchase Agreement
Deferred offering costs included in accounts payable and accrued expenses
Purchase of property and equipment included in accounts payable and accrued expenses
Extinguishment of royalty purchase liability upon sale of dismutase mimetics assets
Issuance of Series B redeemable convertible preferred stock in asset acquisition
Accretion (amortization) of redeemable convertible preferred stock to redemption value
Subscription receivable in connection with private placement
Derecognition of lease liability and right-of-use asset due to lease termination
Acquisition costs in accounts payable
Right-of-use asset obtained in exchange for lease obligation
Sale of property and equipment in exchange for prepaid future services
Reclassification of warrant liability to additional paid-in capital

Comments